Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Dhiraj Yadav

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7078-9893; OpenAlex author ID A5042385064, A5104052682, A5126665650; NIH RePORTER profile ID 8778732. Sources: OpenAlex.

Their work

Papers
23 (first author 3, last author 3)
Trials
0
Grants
4
Labs led
2
Collaborators
82
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper, 1 grant · 2017: none · 2018: 5 papers · 2019: 3 papers · 2020: 5 papers · 2021: 2 papers · 2022: 1 grant · 2023: none · 2024: none · 2025: 2 papers · 2026: 4 papers, 2 grants

Papers 23

  1. Diabetes secondary to chronic pancreatitis and pancreatic cancer: Observations from the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancrea… Last author DOI 10.1016/j.pan.2026.04.001↗
  2. Adult Chronic Pancreatitis Working Group: Goals, Accomplishments and the Path Ahead. A Report From the Consortium for the Study of Chronic Pancreatitis, Diabet… Co-author DOI 10.1097/mpa.0000000000002657↗
  3. Pain profiles in pancreatic cancer and chronic pancreatitis: a multicenter cross-sectional analysis. Co-author DOI 10.3389/fpain.2026.1903789↗
  4. Widespread Hyperalgesia Predicts Mortality in Pancreatic Adenocarcinoma Co-author DOI 10.64898/2026.05.19.26353594↗
  5. Pancreatic cancer-related diabetes and type 2 diabetes differ in multiple aspects of glucose homeostasis. Co-author DOI 10.1007/s00125-025-06543-y↗
  6. Pancreatic adenocarcinoma patients with pain have abnormal central pain processing. Co-author DOI 10.1016/j.pan.2025.04.010↗
  7. Editorial: Introduction to the issue: chronic pancreatitis, diabetes and pancreatic cancer consortium (CPDPC). Co-author DOI 10.1097/mog.0000000000000771↗
  8. Understanding the Contribution of Insulin Resistance to the Risk of Pancreatic Cancer. Last author DOI 10.14309/ajg.0000000000001104↗
  9. Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer: A pilot study of these conditions with and w… Co-author DOI 10.1016/j.pan.2019.11.008↗
  10. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  11. The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsi… Last author DOI 10.1111/apt.15698↗
  12. Letter: the under-treatment and under-diagnosis of pancreatic exocrine insufficiency in chronic pancreatitis and pancreatic cancer is just the tip of the icebe… First author DOI 10.1111/apt.15948↗
  13. Identification of Individuals at Increased Risk for Pancreatic Cancer in a Community-Based Cohort of Patients With Suspected Chronic Pancreatitis. Co-author DOI 10.14309/ctg.0000000000000147↗
  14. Magnetic resonance imaging as a non-invasive method for the assessment of pancreatic fibrosis (MINIMAP): a comprehensive study design from the consortium for t… First author DOI 10.1007/s00261-019-02049-5↗
  15. Reply to: The Relationship of Acute Pancreatitis and Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001358↗
  16. Reporting Standards for Chronic Pancreatitis by Using CT, MRI, and MR Cholangiopancreatography: The Consortium for the Study of Chronic Pancreatitis, Diabetes,… Co-author DOI 10.1148/radiol.2018181353↗
  17. Hereditary Pancreatitis in the United States: Survival and Rates of Pancreatic Cancer. Co-author DOI 10.1038/s41395-018-0194-5↗
  18. Prior History of Pancreatitis Accelerates the Development of Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001160↗
  19. Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rational… Co-author DOI 10.1097/mpa.0000000000001168↗
  20. PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies: Rationale and Study Design for PROCEED From the Consortium for the … Co-author DOI 10.1097/mpa.0000000000001170↗
  21. Standard Operating Procedures for Biospecimen Collection, Processing, and Storage: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pan… Co-author DOI 10.1097/mpa.0000000000001171↗
  22. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Co-author DOI 10.1016/s2468-1253(16)30106-6↗
  23. The epidemiology of pancreatitis and pancreatic cancer. Co-author DOI 10.1053/j.gastro.2013.01.068↗

Grants 4

  1. Parallel-group randomized controlled trial of Pioglitazone versus empagliflozin for T3cDM: The PEP-DM Trial R01DK137868↗
  2. UPMC Clinical Center for the Study of Chronic Pancreatitis and Diabetes U01DK108306↗
  3. SpHincterotomy for Acute Recurrent Pancreatitis U01DK116743↗
  4. Minor Endoscopic Sphincterotomy for Recurrent Acute Pancreatitis with Pancreas Divisum U34DK112673↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yogish C. Kudva · 4 shared papers, 1 shared grant, 2016–2026 · strength 1.83
  2. Frederico G. S. Toledo · 3 shared papers, 1 shared grant, 2021–2026 · strength 1.53
  3. Randall E. Brand · 5 shared papers, 1 shared grant, 2018–2026 · strength 1.52
  4. David Clement Whitcomb · 6 shared papers, 1 shared grant, 2018–2026 · strength 1.33
  5. Christopher E Forsmark · 7 shared papers, 2016–2026 · strength 1.04
  6. Anna Evans Phillips · 5 shared papers, 2018–2026 · strength 1.01
  7. Walter Gwang-Up Park · 7 shared papers, 2018–2026 · strength 1.01
  8. Phil A. Hart · 7 shared papers, 2016–2026 · strength 0.91
  9. Dana K. Andersen · 6 shared papers, 2016–2026 · strength 0.90
  10. Stephen Jacob Pandol · 7 shared papers, 2016–2026 · strength 0.84
  11. Melena D. Bellin · 5 shared papers, 2016–2026 · strength 0.79
  12. Gregory A. Coté · 2 shared grants, 2016–2022 · strength 0.77
  13. Asbjørn Mohr Drewes · 3 shared papers, 2025–2026 · strength 0.75
  14. Marko Damm · 3 shared papers, 2025–2026 · strength 0.75
  15. Vikesh K. Singh · 3 shared papers, 2025–2026 · strength 0.75
  16. Mahya Faghih · 3 shared papers, 2025–2026 · strength 0.75
  17. Søren Schou Olesen · 3 shared papers, 2025–2026 · strength 0.75
  18. Jonas Rosendahl · 3 shared papers, 2025–2026 · strength 0.75
  19. Daniel A. Laheru · 3 shared papers, 2025–2026 · strength 0.75
  20. Evan L Fogel · 5 shared papers, 2018–2026 · strength 0.70
  21. José Serrano · 6 shared papers, 2018–2026 · strength 0.69
  22. Darwin Lewis Conwell · 6 shared papers, 2018–2026 · strength 0.63
  23. Mark Goodarzi · 4 shared papers, 2016–2026 · strength 0.56
  24. Valerie L Durkalski · 1 shared grant, 2022 · strength 0.52
  25. Marie-Theres Kassik · 2 shared papers, 2026 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.